Trial NCT00707655

View at ClinicalTrials.gov 
Org. Study IDs: GEN207

Last trial update was posted on 2023-08-03

MeSH Interventions

Zalutumumab

MeSH Conditions

Carcinoma Carcinoma, Squamous Cell Head and Neck Neoplasms

Other Conditions

Head and Neck Cancer Squamous Cell Carcinoma

Stopping Reasons

The decision is based on company re-evaluation of indications to be pursued within SCCHN

Limitations And Caveats

All adverse events were collected during the 8 week treatment period and for 4 additional weeks. Serious adverse events were collected for the extended follow-up period of 2 years.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID